1.Clinical Observation of Montelukast Combined with Budesonide in the Treatment of Bronchial Asthma in Children
China Pharmacy 2017;28(14):1981-1984
OBJECTIVE:To investigate clinical efficacy and safety of montelukast combined with budesonide in the treatment of bronchial asthma(BA),and it effects on clinical symptom,inflammatory factor and immune function of BA children. METHODS:To-tally 106 BA children selected from pediatrics department of our hospital during Jan. 2014-Dec. 2015 were divided into observation group and control group according to random number table,with 53 cases in each group. Based on routine treatment,control group was given Budesonide suspension for inhalation 400μg,bid. Observation group was additionally given Montelukast sodium tablets oral-ly,4 mg for under 5 years old,qd,5 mg for 5 years old or older,qd,on the basis of control group. Treatment courses of 2 groups last-ed for 8 weeks. Clinical efficacies of 2 groups were compared as well as clinical symptom scores,inflammatory factor and immune fac-tor levels before and after treatment. The occurrence of ADR was also compared between 2 groups. RESULTS:The total response rate of observation group(94.34%)was significantly higher than that of control group(77.36%);the symptom relief time and lung signs disappearance time were significantly shorter than control group,with statistical significance(P<0.05). Before treatment,there was no statistical significance in clinical symptom scores,inflammatory factor and immune factor levels between 2 groups(P>0.05). After treatment,daytime and nighttime symptom scores,the levels of IL-6,IL-8,TNF-αand IgE in 2 groups were significantly decreased, while the levels of IgA and IgG were increased significantly;the observation group was significantly better than control group,with sta-tistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(5.66% vs. 7.55%) (P<0.05). CONCLUSIONS:Montelukast combined with budesonide help to reduce the level of serum inflammatory cytokines in BA children,improve immune function and clinical symptoms with good safety.
2.A study on the effects of PPARγ ligand rosiglitazone in the growth of MGC803 cells transplanted into subrenal-capsule of mice
Lihui ZHU ; Li ZHANG ; Dazhi ZHONG
Cancer Research and Clinic 2008;20(3):155-157
Objective To investigate the inhibitory effects of PPARγ ligand rosiglitazone in vivo of mice which were transplanted the human gastric carcinoma cells line MGC803 into subrenal-capsule.Methods To establish kunming mouse tumor modles of MGC803 cells transplanted into subrenal-capsule and assay the inhibiting growth effects of 50 mg/kg rosiglitazone which were continuously poured into mice gastric for five days by the dissect microscope and HE stain.Results Rosiglitazone could inhibit the growth of MGC803 cells transplanted into subrenal-capsule of mice in vivo by inhibiting proliferation and inducting apoptosis,the tumor inhibitory rate was 62.9%.Conclusion PPARγ ligand rosiglitazone can inhibit the growth of MGC803 cells transplanted into subrenal-capsule of mice in vivo.
3.The diagnosis and treatment of bile duct injury during laparoscopic cholecystectomy (A report of 22 cases)
Zhong CUI ; Lihui ZHANG ; Qingtao ZHAO
Chinese Journal of Minimally Invasive Surgery 2001;0(01):-
Objective To study the prevention and treatment of bile duct injury during laparoscopic cholecystectomy(LC). Methods 22 cases of bile duct injury during LC were reviewed retrospectively. The features, diagnosis, treatment and efficacy of injury were summarized. Results All patients were successfully treated by Roux-en-Y cholangio-jejunostomy. Besides, 8 patients underwent plastic operation of bile duct of hepatic portal and 3 patients middle lobectomy of liver. 22 cases were followed up at the 1st and 3rd year after surgery, and no bile duct stricture, recurrence of jaundice and cholangitis occurred. Conclusions It's a key to prevent bile duct injury during LC. The management of bile duct injury should be chosen according to injured time, sites and types.
4.Pharmacokinetics and Bioavailability of Two Kinds of Famotidine Capsule in Healthy Volunteers
Guoping ZHONG ; Jianhua WANG ; Lihui HUANG ; Min HUANG
China Pharmacy 2001;0(09):-
OBJECTIVE:To study the pharmacokinetics of two kinds of famotidine capsule from different factories in healthy volunteers and to evaluate the bioavailability of them METHODS:A single oral 40 mg dose of famotidine capsule of reference or test preparation was given to healthy male volunteers according to an open randomized crossover study The plasma concentrations of famotidine were determined by a RP-HPLC method The pharmacokinetic parameters and bioavailability of test preparation were compared with reference preparation RESULTS:The main pharmacokinetic parameters of the reference preparation and the test preparation were as follows:Cmax were(189 9?72 1)?g/L and(170 1?59 6)?g/L;Tmax were(2 5?0 8)h and (2 1?0 8)h;T1/2 were(4 1?0 9)h and(3 8?0 8)h;AUC0~t were (1 031 7?316 7)?g/(L?h)and(1 019 4?290 5)?g/(L?h);AUC0→∞ were(1 123 9?346 0)?g/(L?h)and(1 103 4?312 0)?g/(L?h);The relative bioavailability of reference to test preparation was(101 6?22 6)% CONCLUSION:The results showed that the reference preparation and the test preparation were bioequivalent
5.RFA combined with TACE and ethanol injection for unresectable hepatic carcinoma
Lihui ZHANG ; Zhong CUI ; Qingtao ZHAO ; Dong DU
Chinese Journal of General Surgery 2001;0(09):-
Objective To explore the effect of radiofrequency ablation (RFA) combined with transcatherter arterial chemo-embolization (TACE) and percaulaneous ethanol injection (PEI) for unresectable hepatic malignancies. Methods The clinical data of 41 cases of unresectable liver cancer(URLC)treated by RFA,TACE and PEI were analysed retrospectively. Results There were 30 cases of primary hepatic cancer(PHT) and 11 cases of secondary hepatic cancer in this series.Ultrasound,CT and MRI showed the tumors shrinking or stable in 26 of the 41 patients postoperatively.AFP decreased to normal in 12 cases of 16 AFP positive PHT patients after operation. No severe complication was seen in the series. Conclusions RFA combined with TACE and PEI is a safe, well-tolerated and effective method for unresectable hepatic carcinoma, and may improve the treatment efficacy of URLC.
6.Growth-inhibitory effects of selective cyclooxygenase-2 inhibitor on colon cancer cells and its possible mechanisms
Xiaoqing JIA ; Lihui HAN ; Ning ZHONG ; Fanli MENG ; Ming YAN ; Wenjie LI ; Yanqing LI ; Shangzhong ZHANG
Chinese Journal of Pathophysiology 2005;21(5):985-989
AIM: To evaluate the growth-inhibitory effects of NS-398, a selective cyclooxygenase-2 inhibitor, in human colon cancer HT-29 cells and its possible mechanisms. METHODS: MTT assay was applied to detect the cell proliferation. Flow cytometry was performed to detect apoptosis rate and cell cycle. RT-PCR was used to detect the expression of bcl-2 mRNA and bax mRNA. Alteration of cytoskeleton component F-actin was observed by confocal laser scanning microscope. RESULTS: NS-398 could inhibit growth of HT-29 cells in dose-and time-dependent manners. Flow cytometry revealed that NS-398 could induce apoptosis and cause G0/G1 arrest of HT-29 cells in a dose-dependent manner. After 72 h incubation with NS-398 at different concentrations, the expression level of bcl-2 mRNA was lowered and the ratio of bcl-2 to bax was decreased in HT-29 cells. F-actin was mainly distributed around nuclei forming annular structure in HT-29 cells. After exposure to NS-398, the annular structure around nuclei disappeared and fluorescence intensity of F-actin decreased obviously. CONCLUSION: NS-398 can inhibit the growth effectively and induce apoptosis in HT-29 cells in vitro, which is associated with the down-regulation of bcl-2 to bax ratio and the disruption of cytoskeleton.
7.Study on Pharmacokinetics and Bioavailability of Ranitidine Hydrochloride Capsule in Human Body
Guoping ZHONG ; Min HUANG ; Lihui HUANG ; Guixiong ZENG ; Xueding WANG ; Cheng TANG
China Pharmacy 2005;0(14):-
OBJECTIVE:To study the pharmacokinetics and bioequivalence of both domestic ranitidine hydrochloride capsules and imported ranitidine hydrochloride tablets.METHODS:20healthy volunteers were randomized into groups,whose plasma concentrations of ranitidine were determined at different time after single oral dose of300mg ranitidine hydrochloride capsule or ranitidine hydrochloride tablets300mg by own control by a RP-HPLC method,the pharmacokinetic parameters were computed and which were experienced variance analysis and two-way t-tests and one-way t-tests.RESULTS:The respective pharmacokinetic parameters of ranitidine hydrochloride tablets and ranitidine hydrochloride capsuless were as fol?lows,the C max were(1247.1?547.5)?g/L and(1294.8?613.2)?g/L;t max were(2.98?0.73)h and(2.73?0.80)h;t 1/2 were(3.17?0.36)h and(3.33?0.42)h;AUC 0~t were(5805.9?1403.5)(?g?h)/L and(5941.2?1526.3)(?g?h)/L;AUC 0~∞ were(6163.8?1456.4)(?g?h)/L and(6351.8?1652.7)(?g?h)/L;The relative bioavailability of the ranitidine hydrochloride capsules to ranitidine hydrochloride tablets was(104.3?24.3)%.CONCLUSION:Ranitidine hydrochloride capsules and the ranitidine hydrochloride tablets were bioequivalent.
8.Nursing points about using the polysiloxane impression material in the repair of the precise attachment
Yanfei HUANG ; Xiaobo PAN ; Aixi ZHONG ; Lihui PENG ; Guangxue LIU ; Rongting LI
Chinese Journal of Practical Nursing 2006;0(20):-
Objective To study the effects of using the polysiloxane impression material in the repair of the precise attachment.Method Using the Rapid polysiloxane impression material to make 37 work impressions,29 un-work impressions were made by alginate impression material.Results All the work impressions were eligible while there were 4 un-work impressions not eligible at the first time. Conclusion The effects of using the polysiloxane impression material in the repair of the precise attachment is satisfactory.
9.Evaluation of genomic amplification of the human telomerase RNA component gene in the screening of cervical lesions
Jing JIANG ; Zheng TU ; Guo ZHANG ; Jingran LI ; Lijun ZHAO ; Chao ZHAO ; Shuhui CUI ; Xiaoping LI ; Zhong CHEN ; Lihui WEI
Chinese Journal of Obstetrics and Gynecology 2008;43(11):849-853
Objective To investigate the genomic amplification of the human telomerase RNA component (hTERC) gene in cervical cytology and evaluate its role in screening of cervical lesions. Methods A total of 301 cases were recruited, with liquid-based cytology diaghoses as normal (n=203), atypical squamous cells (ASC, n=66), low-grade squamous intraepithelial lesions ( LSIL,n=18), and high-grade squamous intraepithelial lesions ( HSIL, n=14). Following cytological examination, the slides were analyzed using a two-color fluorescence in aitu hybridization ( FISH ) probe targeted to chromosome 3q26 containing hTERC. The hTERC findings were compared to the cytologic and histologie results, as well as high-risk human papilloma viruses (HPV) results. Results Genomie amplification of hTERC was found in 3.0% (6/203)of normal specimens, 21.2% (14/66) of ASC, 44.4% (8/18) of LSIL and 92.9% (13/14) of HSIL, with a significant difference in each pair wise (all P<0.05). Significantly more cells with 3q26 gain were found in cervical intraepithelial lesion (CIN) Ⅱ than in CIN Ⅰ(75.0% vs. 20.0% ), as well as in CIN Ⅲ (86.7% vs. 20.0% ) and squamous cervical cancer (SCC) than in CIN Ⅰ (100.0% vs. 20.0%) ( all P<0.01). The sensitivity of hTERC amplification was significantly higher than cytological screening (82.6% vs. 17.4%, P<0.01), and its specificity was higher than high-risk HPV test (67.8%-73.5% vs. 25.6%-27.7%, P<0.01) in the diagnosis of HSIL (CIN Ⅱ - Ⅲ). The abnormal hTERC signal type mostly was 2:3 in CIN Ⅰ (84.9% ) ; whereas in CIN Ⅱ-Ⅲ, 2: 3, 2:4 and 4:4 accounted for 44.6%, 24.8% and 17.8%, respectively. Conclusion Testing the gain of chromosome 3q26 in cytological specimens using specific probe for hTERC is powerful in screening of HSIL, and the amplification patterns of 2:4 and 4:4 may serve as potential prognosis markers.
10.Study of zinc in protecting sperm from sodium nitroprusside damage.
Maigui YANG ; Yang YANG ; Zhuying ZHANG ; Xiaoke HAO ; Shanluan ZHENG ; Lihui ZHONG ; Ailing FAN ; Wei XU
National Journal of Andrology 2004;10(7):530-537
OBJECTIVETo study the function of zinc in preventing human sperm from being damaged by sodium nitroprusside (SNP), an external NO donor.
METHODSAnalyses were made of the function of zinc in protecting sperm from being influenced by SNP in such aspects as sperm motility, head-tail connection and the breakage of sperm DNA chain by using phase-contrast microscope and single cell gel electrophoresis (SCGE).
RESULTSSperm motility was obviously inhibited by SNP. The percentage of comet cells increased significantly but the stability of sperm head-tail connection decreased. Zinc could promote sperm motility, protect the DNA chain and prevent the sperm head-tail connection from breaking.
CONCLUSIONZinc can protect sperm from being damaged by NO. Its mechanism may be related to the mercaptol group of sperm chromatin.
Adult ; DNA Damage ; Humans ; Male ; Nitric Oxide ; toxicity ; Nitroprusside ; toxicity ; Spermatozoa ; drug effects ; Zinc ; pharmacology